| Patient no |
Sex |
Age (years) |
Duration of disease (years) |
Treatment prior to infliximab |
VA at the initiation of infliximab*RE-LE |
VA at last visit on infliximab*RE-LE |
Concomitant immunosuppressive |
Ocular inflammatory attacks |
relapse time (months) |
INAH prophylaxis |
Duration of infliximab therapy (months) |
Last follow up status |
| 1 |
F |
28 |
3 |
Cyc-A***
IFN α-2a |
20/40 20/20 |
20/32 20/20 |
AZA, Cyc-A
Started at 2nd month |
MAU**
PU |
9
2 |
— |
15 |
Switched to adalimumab |
| 2 |
F |
31 |
1 |
CS, AZA***
IFN α-2a |
20/40 20/25 |
20/40 20/20 |
AZA
Started at 3rd month |
PU
MAU |
3
6 |
— |
8 |
Discontinued due to (HPV+genital warts) |
| 3 |
M |
38 |
8 |
CS, AZA, Cyc-A |
20/200 20/32 |
20/50 20/32 |
AZA |
None |
— |
— |
8 |
Discontinued |
| 4 |
M |
38 |
10 |
IFN α-2a |
20/640 20/640 |
20/800 20/500 |
— |
MAU |
5 |
+ |
7 |
Out of follow-up |
| 5 |
M |
30 |
8 |
CS, AZA, Cyc-A |
NLP 20/200 |
HM 20/200 |
CS, Cyc-A
CS started at 4th month |
PU |
4 |
+ |
33 |
Continues infliximab |
| 6 |
M |
32 |
11 |
CS, AZA, Cyc-A |
20/400 20/63 |
20/640 20/32 |
— |
None |
— |
— |
23 |
Discontinued |
| 7 |
M |
41 |
7 |
CS, AZA, Cyc-A |
20/1250 20/100 |
20/200 20/100 |
— |
MAU |
8 |
+ |
11 |
Discontinued |
| 8 |
M |
49 |
28 |
CS, AZA, Cyc-A |
NLP 20/25 |
NLP 20/25 |
— |
None |
— |
+ |
18 |
Continues infliximab |
| 9 |
M |
36 |
9 |
CS, AZA, Cyc-A |
LP HM |
HM 20/200 |
AZA |
None |
— |
— |
7 |
Continues infliximab |
*VA: Visual Acuity; RE: Right Eye; LE: Left eye.
**+1 anterior chamber reaction developed and persisted for following six months.
***Cyc-A and AZA were used before.
LP: Light Perception; NLP: No Light Perception; HM: Hand Motion; CS: Corticosteroids; Cyc-A: Cyclosporin-A; AZA: Azathioprine; IFN α-2a: Interferon-α-2a; MAU: Mild
Anterior Uveitis; PU: Posterior Uveitis |
